Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates

• Published in: Nature communications Vol. 13; no. 1; pp. 1699 - 9
• Main Authors: Pavot, Vincent, Berry, Catherine, Kishko, Michael, Anosova, Natalie G., Huang, Dean, Tibbitts, Tim, Raillard, Alice, Gautheron, Sylviane, Gutzeit, Cindy, Koutsoukos, Marguerite, Chicz, Roman M., Lecouturier, Valerie
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 31.03.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 631/250/590/2294; 631/326/596/4130; 692/308/2778; 692/699/255/2514; Animals; Antibodies; Antibodies, Viral; Clinical trials; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Cross-protection; Humanities and Social Sciences; Humans; mRNA; multidisciplinary; Neutralization; Neutralizing; Primates; Proteins; SARS-CoV-2 - genetics; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Spike protein; Vaccine efficacy; Vaccines; Viral diseases; Viral Vaccines

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 p...